Catalog No.A2010 Synonyms: LU200134, D2E7 Non-humanized mouse model applicable
For research use only. Not for use in humans.
Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD.
Choose Selective TNF-alpha Inhibitors
|Description||Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD.|
Adalimumab blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. Through its anti-TNF actions, adalimumab reduces concentrations of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, reduces of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, and reduces concentrations of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-1β mRNA, IL-1 receptor antagonist, IL-6).
|In vivo||Adalimumab is safe and well tolerated. In healthy adults, the average absolute bioavailability of adalimumab 40 mg administered subcutaneously (s.c.) is 64%. Concentrations in the synovial fluid are 31-96% of those of the serum. Maximum plasma concentrations occur at 131 (± 56) h, and the mean half-life is ∼ 2 weeks (range, 10-20 days). Adalimumab treatment attenuates the Ovalbumin(OVA)-induced increase in serum IgE, TH2 and TH1 derived inflammatory cytokines (IL-4 and IFN-γ, respectively) in bronchoalveolar lavage (BAL) fluid, suppresses recruitment of inflammatory cells in BAL fluid and lung, and inhibits BAL fluid neutrophilia. It also ameliorates goblet cell metaplasia and bronchial fibrosis.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles.|
If you have any other enquiries, please leave a message.